SMAD4 and familial pancreatic carcinoma: A study in patients with advanced pancreatic cancer did not detect survival benefit with the addition of HCQ to gemcitabine and nab‐paclitaxel,19, 32 however, a dedicated subgroup analysis to SMAD4 has not been performed.